Congress on Pharmaceutical r & d summit

The absence of a significant difference in the rate of active ingredient pharmaceutical equivalents or pharmaceutical alternative at site of action is applicable, is defined as bioequivalence.

Los Angeles, CA (prHWY.com) January 5, 2013 - The 4th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R & D Summit would be organized by the OMICS Group at DoubleTree by Hilton Beijing, China, from May 20-22, 2013. The meet is labeled BABE-2013 and would feature 11 tracks and 77 sessions. The conference would invite professionals in the bioequivalence discipline to deliver talk about latest research findings with respect to the theme "Advanced Discussions of the Current Issues & Analyzing the Novel Approaches of Bioavailability & Bioequivalence."

The comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes animal death, is called the therapeutic index. To achieve this equivalence, geometric mean ratios are taken. The therapeutic agent is concentrated in its area of effect, a phenomenon known as targeting, that in turn brings variation in effective therapeutic index.
The certain safety factor in the context of bioequivalence is defined as ratio of lethal dose for 1% population to the effective dose for 99% of population. Bioavailability and Bioequivalence conference gives insights into the latest development on the field. The proceedings of the meet also provide practical exposure to various instrumental techniques in accordance with the requirements of bioequivalence. A bioanalyis conference involves discussions on using and evaluating the scope of recent research in the domain.

For more details please visit:
http://www.omicsgroup.com/conferences/bioequivalence-bioavailability-2013/

###

Tag Words: bioavailability, bioequivalence

Categories: Health

Link To This Press Release:

URL HTML Code